AERI Projected Dividend Yield
Aerie Pharmaceuticals Inc ( NASDAQ : AERI )Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease. 20 YEAR PERFORMANCE RESULTS |
AERI Dividend History Detail AERI Dividend News AERI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |